PT2114447E - Prevention and treatment of sub-clinical pcvd - Google Patents
Prevention and treatment of sub-clinical pcvd Download PDFInfo
- Publication number
- PT2114447E PT2114447E PT87088779T PT08708877T PT2114447E PT 2114447 E PT2114447 E PT 2114447E PT 87088779 T PT87088779 T PT 87088779T PT 08708877 T PT08708877 T PT 08708877T PT 2114447 E PT2114447 E PT 2114447E
- Authority
- PT
- Portugal
- Prior art keywords
- prevention
- sub
- treatment
- clinical
- pcvd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20070102250 EP1958644A1 (en) | 2007-02-13 | 2007-02-13 | Prevention and treatment of sub-clinical pcvd |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2114447E true PT2114447E (en) | 2013-10-10 |
Family
ID=38191300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT87088779T PT2114447E (en) | 2007-02-13 | 2008-02-11 | Prevention and treatment of sub-clinical pcvd |
Country Status (23)
Country | Link |
---|---|
US (5) | US7943298B2 (en) |
EP (3) | EP1958644A1 (en) |
JP (1) | JP5562041B2 (en) |
KR (1) | KR101521465B1 (en) |
CN (1) | CN101610786B (en) |
AR (1) | AR065319A1 (en) |
AU (1) | AU2008214639B2 (en) |
BR (1) | BRPI0807493A2 (en) |
CA (1) | CA2676568C (en) |
CL (1) | CL2008000445A1 (en) |
CY (1) | CY1114577T1 (en) |
DK (2) | DK2114447T3 (en) |
ES (2) | ES2555132T3 (en) |
MX (1) | MX2009008577A (en) |
MY (1) | MY152149A (en) |
PL (1) | PL2114447T3 (en) |
PT (1) | PT2114447E (en) |
RU (1) | RU2520759C2 (en) |
SI (1) | SI2114447T1 (en) |
TW (1) | TWI438003B (en) |
UA (1) | UA100507C2 (en) |
WO (1) | WO2008098909A1 (en) |
ZA (1) | ZA200904806B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
UA95602C2 (en) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Pcv2 immunogenic compositions and methods of producing such compositions |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
CN102698263B (en) | 2005-12-29 | 2016-07-06 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Multivalent pcv 2 immunogenic compositions and the method preparing such composition |
ES2572736T3 (en) | 2005-12-29 | 2016-06-02 | Boehringer Ingelheim Vetmedica, Inc. | Use of an immunogenic composition to attenuate clinical symptoms in pigs |
US20100136060A1 (en) * | 2006-11-22 | 2010-06-03 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing porcine circovirus-associated disease outbreaks |
EP2101815A4 (en) | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
AU2007333857B2 (en) | 2006-12-15 | 2014-05-15 | Boehringer Ingelheim Animal Health USA Inc. | Treatment of pigs with PCV2 antigen |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
KR20100113582A (en) | 2008-01-23 | 2010-10-21 | 베링거잉겔하임베트메디카인코퍼레이티드 | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
EP2254595A4 (en) * | 2008-02-15 | 2012-12-05 | Boehringer Ingelheim Vetmed | Methods and compositions for reducing the impact of enteric diseases |
RU2528750C2 (en) * | 2008-11-19 | 2014-09-20 | Лабораторио Ави-Мекс, С.А. Де С.В. | Recombinant vaccine of inactivated viral vector |
AR078253A1 (en) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | METHODS TO REDUCE ANTIVIRICAL ACTIVITY IN PCV-2 COMPOSITIONS AND PCV-2 COMPOSITIONS WITH BETTER IMMUNOGENICITY |
EP2590673A4 (en) | 2010-07-08 | 2016-03-30 | United Biomedical Inc | Designer peptide-based pcv2 vaccine |
WO2014182872A1 (en) | 2013-05-08 | 2014-11-13 | Protatek International, Inc. | Vaccine for pcv2 and mycoplasma |
US20140348874A1 (en) * | 2013-05-22 | 2014-11-27 | Boehringer Ingelheim Espana, S.A. | Method for the reduction of pcv-2 in a herd of swine |
ES2778425T3 (en) | 2013-10-02 | 2020-08-10 | Boehringer Ingelheim Animal Health Usa Inc | PCV2 ORF2 protein variant and virus-like particles composed of it |
BR112016012435A8 (en) * | 2013-12-03 | 2018-01-30 | Intervet Int Bv | vaccine, and uses of a recombinantly expressed porcine circovirus type 2 orf2 protein |
KR102055215B1 (en) * | 2015-12-28 | 2020-01-22 | 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 | Porcine circovirus type 2 capsid protein and method of preparing a pharmaceutical composition comprising the same |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
ZA881694B (en) * | 1987-03-17 | 1988-09-06 | Akzo N.V. | Adjuvant mixture |
US5069901A (en) | 1988-02-03 | 1991-12-03 | Jones Elaine V | Preparation of a recombinant subunit vaccine against pseudorabies infection |
DK0454735T3 (en) | 1989-01-23 | 1996-10-07 | Auspharm Int Ltd | Vaccine composition |
US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
US5202430A (en) | 1990-01-16 | 1993-04-13 | University Of Tennessee | Transmissible gastroenteritis virus genes |
WO1991018627A1 (en) | 1990-05-29 | 1991-12-12 | Smithkline Beecham Corporation | Swine pneumonia vaccine and method for the preparation thereof |
US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
GB9023111D0 (en) | 1990-10-24 | 1990-12-05 | Wellcome Found | Expression system |
WO1992007934A1 (en) | 1990-11-01 | 1992-05-14 | Iowa State University Research Foundation, Inc. | Bacterial attenuation method and vaccine |
US6042830A (en) | 1992-08-05 | 2000-03-28 | Boehringer Ingelheim Vetmedica, Inc. | Viral agent associated with mystery swine disease |
MX9204885A (en) | 1991-08-26 | 1994-05-31 | Boehringer Animal Health Inc | VACCINE COMPOSITION INCLUDING VIRUSES OF INFERTILITY AND RESPIRATORY SYNDROME OF PIGS. |
US5580557A (en) | 1991-10-09 | 1996-12-03 | Iowa State University Research Foundation, Inc. | Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
ZA953703B (en) | 1994-05-10 | 1996-01-10 | American Home Prod | Modified live BRSV vaccine |
US5885823A (en) | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
WO1998006855A1 (en) | 1996-08-16 | 1998-02-19 | The Texas A & M University System | Compositions and methods for delivery of nucleic acids to hepatocytes |
DE69704011T2 (en) | 1996-10-09 | 2001-06-07 | Akzo Nobel Nv | Swine Reproductive System Respiratory Syndrome Virus (PRRSV) vaccine strains |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
US7211379B2 (en) | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
UA78180C2 (en) | 1997-10-03 | 2007-03-15 | Меріаль | Porcine circovirus, vaccines and diagnostic reagents |
US7192594B2 (en) | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
FR2781159B1 (en) | 1998-07-06 | 2000-10-06 | Merial Sas | CIRCOVIRUS VACCINE AND PIG PARVOVIRUS |
US20060029617A1 (en) | 1997-10-03 | 2006-02-09 | Charreyre Catherine E | Porcine circovirus and Helicobacter combination vaccines and methods of use |
US20040062775A1 (en) * | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
FR2772047B1 (en) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION |
EP1037909B1 (en) | 1997-12-11 | 2007-06-13 | University of Saskatchewan | Postweaning multisystemic wasting syndrome virus from pigs |
US6287856B1 (en) | 1998-03-13 | 2001-09-11 | University Of Georgia Research Foundation, Inc. | Vaccines against circovirus infections |
US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
WO2000031275A1 (en) | 1998-11-19 | 2000-06-02 | Azwell Inc. | Recombinant lysophosphatidic acid phosphatase |
FR2789695B1 (en) | 1999-02-11 | 2003-03-07 | Merial Sas | VIRAL VACCINES AND VACCINES BASED ON RECOMBINANT AND REPLICATIVE SWINE ADENOVIRUSES |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
US6943152B1 (en) * | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
WO2001017556A1 (en) | 1999-09-07 | 2001-03-15 | Shionogi & Co., Ltd. | Vaccine preparations for mucosal administration |
US6656478B1 (en) | 1999-11-12 | 2003-12-02 | Samuel D. Charles | Cross-protective salmonella vaccines |
AU784557B2 (en) | 1999-12-21 | 2006-05-04 | Merial | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
US6808900B2 (en) * | 2000-06-15 | 2004-10-26 | Manitoba, University Of | Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
EP1290016A2 (en) | 2000-06-15 | 2003-03-12 | Purdue Research Foundation | Vaccine for congenital tremors in pigs |
DK1303265T3 (en) | 2000-07-20 | 2007-11-12 | Lauras As | Use of COX-2 inhibitors as immunostimulants in the treatment of HIV or AIDS |
US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
JP2002247979A (en) | 2001-02-23 | 2002-09-03 | Nippon Biologicals Inc | Marek's disease vaccine and method for producing the same |
PL202951B1 (en) | 2001-03-27 | 2009-08-31 | Univ Saskatchewan | Methods to culture circovirus |
US20030096377A1 (en) | 2001-06-28 | 2003-05-22 | Virginia Tech Intellectual Properties, Inc. | Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2 |
DK2027873T3 (en) * | 2001-07-02 | 2015-11-09 | Zoetis Services Llc | Single Dose Vaccination with Mycoplasma hyopneumoniae |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US7276353B2 (en) * | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US7279166B2 (en) | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US6841364B2 (en) | 2002-01-22 | 2005-01-11 | Protatek International, Inc. | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof |
US20040063188A1 (en) | 2002-02-14 | 2004-04-01 | Novavax, Inc. | Kit for treating gastrointestinal tract |
WO2003077860A2 (en) | 2002-03-13 | 2003-09-25 | Biophysica, Inc. | BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES |
US20030215455A1 (en) * | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
US7223207B1 (en) | 2002-09-13 | 2007-05-29 | Simon Basyuk | Exercise and massage device |
AU2002951692A0 (en) | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
US7408636B2 (en) | 2002-10-31 | 2008-08-05 | Chemimage Corporation | Method and apparatus for dark field chemical imaging |
AU2004209985B2 (en) | 2003-02-03 | 2008-09-18 | Cerebus Biologicals, Inc. | Methods for treating, preventing and detecting Helicobacter infection |
US7563449B2 (en) | 2003-04-21 | 2009-07-21 | Pfizer Inc, | Methods for reducing cattle reproductive diseases |
CN1458167A (en) | 2003-06-02 | 2003-11-26 | 中国农业科学院哈尔滨兽医研究所 | Truncated expressed porcine circovirus II capsid protein antigen and use thereof |
US7335361B2 (en) * | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
NZ545289A (en) | 2003-07-24 | 2008-05-30 | Merial Ltd | Vaccine formulations comprising an oil-in-water emulsion |
PL1651260T5 (en) * | 2003-07-25 | 2018-11-30 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof |
FR2861731B1 (en) * | 2003-10-30 | 2006-02-24 | Centre Nat Rech Scient | NOVEL PHOSPHATE FIXATION PROTEIN, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USES THEREOF |
WO2005112995A1 (en) | 2004-04-26 | 2005-12-01 | Choongang Vaccine Laboratory Co., Ltd. | Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof |
CN1579553A (en) | 2004-05-18 | 2005-02-16 | 浙江大学 | Method for preparing II-type pig's ring-virus nucleic vaccine and the use thereof |
KR100478845B1 (en) | 2004-06-22 | 2005-03-24 | 채찬희 | Biological composition for preventing and treating pmws |
JP2008505114A (en) | 2004-06-30 | 2008-02-21 | アイディー バイオメディカル コーポレイション オブ ケベック | Vaccine composition for treating coronavirus infection |
US7700285B1 (en) * | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US7833707B2 (en) * | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
UA95602C2 (en) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Pcv2 immunogenic compositions and methods of producing such compositions |
ES2343201T3 (en) | 2005-01-13 | 2010-07-26 | Boehringer Ingelheim Vetmedica Gmbh | VACCINES AGAINST THE SRRP. |
US7300785B2 (en) | 2005-02-03 | 2007-11-27 | Universiteit Ghent | Culturing circular ssDNA viruses for the production of vaccines |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
MX2007012786A (en) | 2005-04-13 | 2008-01-11 | Merial Ltd | Method for porcine circovirus production and assays for monitoring production. |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
PL1926496T3 (en) | 2005-09-09 | 2014-02-28 | Intervet Int Bv | Pcv-2 vaccine |
CN102698263B (en) * | 2005-12-29 | 2016-07-06 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Multivalent pcv 2 immunogenic compositions and the method preparing such composition |
ES2572736T3 (en) | 2005-12-29 | 2016-06-02 | Boehringer Ingelheim Vetmedica, Inc. | Use of an immunogenic composition to attenuate clinical symptoms in pigs |
US20100136060A1 (en) | 2006-11-22 | 2010-06-03 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing porcine circovirus-associated disease outbreaks |
EP2101815A4 (en) | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
AU2007333857B2 (en) | 2006-12-15 | 2014-05-15 | Boehringer Ingelheim Animal Health USA Inc. | Treatment of pigs with PCV2 antigen |
EP1941903A1 (en) * | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
GB0712160D0 (en) * | 2007-06-22 | 2007-08-01 | Univ Ghent | Methods and compositions in the treatment of procine circoviral infection |
US20090017064A1 (en) | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
KR20100113582A (en) | 2008-01-23 | 2010-10-21 | 베링거잉겔하임베트메디카인코퍼레이티드 | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
EP2254595A4 (en) | 2008-02-15 | 2012-12-05 | Boehringer Ingelheim Vetmed | Methods and compositions for reducing the impact of enteric diseases |
US8444989B1 (en) | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
US20100150959A1 (en) | 2008-12-15 | 2010-06-17 | Vectogen Pty Ltd. | PCV 2-Based Methods and Compositions for the Treatment of Pigs |
AR078253A1 (en) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | METHODS TO REDUCE ANTIVIRICAL ACTIVITY IN PCV-2 COMPOSITIONS AND PCV-2 COMPOSITIONS WITH BETTER IMMUNOGENICITY |
US20110150770A1 (en) | 2009-12-18 | 2011-06-23 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine |
RS59952B1 (en) | 2010-03-16 | 2020-03-31 | Virginia Tech Intellectual Properties Inc | Live attenuated chimeric porcine circovirus vaccine |
US9580474B2 (en) | 2010-09-08 | 2017-02-28 | The Johns Hopkins University | Polyionic papilloma virus-like particle (VLP) vaccines |
CN103122352B (en) | 2012-09-27 | 2015-02-11 | 华中农业大学 | Porcine circovirus II-type recombinant baculovirus as well as preparation method and application thereof |
EP3587439A3 (en) | 2013-03-01 | 2020-03-11 | Boehringer Ingelheim Animal Health USA Inc. | Improved quantification of vaccine compositions |
WO2014179200A1 (en) | 2013-04-30 | 2014-11-06 | Boehringer Ingelheim Vetmedica, Inc. | Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection |
US20140348874A1 (en) | 2013-05-22 | 2014-11-27 | Boehringer Ingelheim Espana, S.A. | Method for the reduction of pcv-2 in a herd of swine |
DK3035958T3 (en) | 2013-08-23 | 2022-12-12 | Boehringer Ingelheim Animal Health Usa Inc | Svine-circovirus type 2 (pcv2) subunit-vaccine |
ES2778425T3 (en) | 2013-10-02 | 2020-08-10 | Boehringer Ingelheim Animal Health Usa Inc | PCV2 ORF2 protein variant and virus-like particles composed of it |
US10555994B2 (en) | 2015-03-30 | 2020-02-11 | Boehringer Ingelheim Animal Health USA Inc. | PCV2 ORF2 carrier platform |
-
2007
- 2007-02-13 EP EP20070102250 patent/EP1958644A1/en not_active Withdrawn
-
2008
- 2008-02-11 KR KR1020097018931A patent/KR101521465B1/en active IP Right Grant
- 2008-02-11 CN CN2008800049307A patent/CN101610786B/en active Active
- 2008-02-11 BR BRPI0807493-3A patent/BRPI0807493A2/en not_active Application Discontinuation
- 2008-02-11 ES ES12165993.2T patent/ES2555132T3/en active Active
- 2008-02-11 PL PL08708877T patent/PL2114447T3/en unknown
- 2008-02-11 CA CA2676568A patent/CA2676568C/en active Active
- 2008-02-11 SI SI200831057T patent/SI2114447T1/en unknown
- 2008-02-11 EP EP12165993.2A patent/EP2481421B1/en active Active
- 2008-02-11 DK DK08708877.9T patent/DK2114447T3/en active
- 2008-02-11 PT PT87088779T patent/PT2114447E/en unknown
- 2008-02-11 RU RU2009134222/15A patent/RU2520759C2/en active
- 2008-02-11 UA UAA200909228A patent/UA100507C2/en unknown
- 2008-02-11 MY MYPI20093335 patent/MY152149A/en unknown
- 2008-02-11 AU AU2008214639A patent/AU2008214639B2/en active Active
- 2008-02-11 DK DK12165993.2T patent/DK2481421T3/en active
- 2008-02-11 WO PCT/EP2008/051628 patent/WO2008098909A1/en active Application Filing
- 2008-02-11 JP JP2009549822A patent/JP5562041B2/en active Active
- 2008-02-11 EP EP08708877.9A patent/EP2114447B1/en active Active
- 2008-02-11 ES ES08708877T patent/ES2434117T3/en active Active
- 2008-02-11 MX MX2009008577A patent/MX2009008577A/en active IP Right Grant
- 2008-02-12 AR ARP080100605A patent/AR065319A1/en active Pending
- 2008-02-12 TW TW097104856A patent/TWI438003B/en active
- 2008-02-12 CL CL200800445A patent/CL2008000445A1/en unknown
- 2008-02-13 US US12/030,611 patent/US7943298B2/en active Active
-
2009
- 2009-07-08 ZA ZA2009/04806A patent/ZA200904806B/en unknown
-
2011
- 2011-04-04 US US13/079,498 patent/US8496940B2/en active Active
-
2013
- 2013-06-24 US US13/924,811 patent/US9132187B2/en active Active
- 2013-11-06 CY CY20131100982T patent/CY1114577T1/en unknown
-
2015
- 2015-08-06 US US14/820,540 patent/US9555092B2/en active Active
-
2016
- 2016-12-13 US US15/377,469 patent/US9943587B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2114447E (en) | Prevention and treatment of sub-clinical pcvd | |
MX2009006541A (en) | Treatment of prdc in pigs. | |
UA104129C2 (en) | Reduction of concomitant infections in pigs by the use of pcv2 antigen | |
UA103298C2 (en) | Method for the treatment of young piglets by means of pcv2 antigen | |
TW200633719A (en) | Glycoconjugate vaccines containing peptidoglycan | |
WO2008073464A3 (en) | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections | |
WO2009118662A3 (en) | Methods and compositions for treating bone loss | |
GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
MX2007012702A (en) | Use of cd25 antibodies in immunotherapy. | |
GB0712160D0 (en) | Methods and compositions in the treatment of procine circoviral infection | |
UA99708C2 (en) | Single dose of multivalent combination vaccine comprising pcv2 antigen | |
BRPI0717219A2 (en) | "immunogenic composition, method for treating or preventing disease, and use of an immunogenic composition." | |
WO2007030810A3 (en) | Multiparameter whole blood monitor and method | |
UA93201C2 (en) | Antibody neutralizing human tgf beta 1 | |
GB0710529D0 (en) | Vaccine | |
EP1794329A4 (en) | Porcine reproductive and respiratory syndrome isolates and methods of use | |
PL2380584T3 (en) | Immunostimulatory method | |
NZ591950A (en) | Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition | |
TW200731986A (en) | Use of vaccines for the treatment/prevention of the transmission of pathogens | |
HK1097774A1 (en) | Stable pharmaceutical composition comprising linezolid from iv | |
BRPI0910884A2 (en) | immunogenic composition, method for treating or preventing staphylococcal infection or disease, and use of an immunogenic composition. | |
WO2008150275A3 (en) | Methods for preventing and ameiliorating porcine respiratory and reproductive syndrome virus-associated disease by immunizing against porcine ttv infection | |
CY1110620T1 (en) | METHOD OF TREATMENT OF ACUTE PARARRINOKOLPITIDAS | |
WO2003103699A8 (en) | Use of ramoplanin to treat diseases associated with the use of antibiotics | |
UA102145C2 (en) | Immunogenic compositions comprising lawsonia intracellularis |